Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein*
暂无分享,去创建一个
D. Clarke | T. W. Loo | Tip W Loo | David M Clarke | T. Loo
[1] F. Sharom,et al. ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. , 1992, Biochimica et biophysica acta.
[2] S. Chifflet,et al. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. , 1988, Analytical biochemistry.
[3] G. I. Bell,et al. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. , 1986, Nucleic acids research.
[4] P. Borst,et al. Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.
[5] G. L. Kenyon,et al. [40] Novel sulfhydryl reagents , 1977 .
[6] M. Raida,et al. Localization of the Iodomycin Binding Site in Hamster P-glycoprotein* , 1997, The Journal of Biological Chemistry.
[7] D. Clarke,et al. Identification of Residues in the Drug-binding Domain of Human P-glycoprotein , 1999, The Journal of Biological Chemistry.
[8] I. Pastan,et al. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. , 1992, The Journal of biological chemistry.
[9] D. Clarke,et al. Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.
[10] D. Clarke,et al. Identification of Residues in the Drug-binding Site of Human P-glycoprotein Using a Thiol-reactive Substrate* , 1997, The Journal of Biological Chemistry.
[11] P. Melera,et al. Transmembrane domain (TM) 9 represents a novel site in P-glycoprotein that affects drug resistance and cooperates with TM6 to mediate [125I]iodoarylazidoprazosin labeling. , 2001, Molecular pharmacology.
[12] D. Clarke,et al. Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators* , 1997, The Journal of Biological Chemistry.
[13] A. E. Senior,et al. Covalent inhibitors of P-glycoprotein ATPase activity. , 1994, The Journal of biological chemistry.
[14] M. Azzaria,et al. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance , 1989, Molecular and cellular biology.
[15] P. Gros,et al. Transmembrane Organization of Mouse P-glycoprotein Determined by Epitope Insertion and Immunofluorescence (*) , 1996, The Journal of Biological Chemistry.
[16] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[17] I. Pastan,et al. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Béliveau,et al. Identification of the cyclosporin-binding site in P-glycoprotein. , 1998, Biochemistry.
[19] D. Clarke,et al. The human multidrug resistance P‐glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] L. Mayer,et al. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[22] V. Ling,et al. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. , 2001, European journal of biochemistry.
[23] D. Clarke,et al. Defining the Drug-binding Site in the Human Multidrug Resistance P-glycoprotein Using a Methanethiosulfonate Analog of Verapamil, MTS-verapamil* , 2001, The Journal of Biological Chemistry.
[24] D. Clarke,et al. Identification of Residues within the Drug-binding Domain of the Human Multidrug Resistance P-glycoprotein by Cysteine-scanning Mutagenesis and Reaction with Dibromobimane* , 2000, The Journal of Biological Chemistry.
[25] P. Gros,et al. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] Y. Assaraf,et al. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. , 1997, European journal of biochemistry.
[27] D. Clarke,et al. Mutational analysis of human P-glycoprotein. , 1998, Methods in enzymology.
[28] D. Clarke,et al. The Transmembrane Domains of the Human Multidrug Resistance P-glycoprotein Are Sufficient to Mediate Drug Binding and Trafficking to the Cell Surface* , 1999, The Journal of Biological Chemistry.
[29] D. Clarke,et al. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.
[30] I. Pastan,et al. Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. , 1989, The Journal of biological chemistry.
[31] D. Clarke,et al. Covalent Modification of Human P-glycoprotein Mutants Containing a Single Cysteine in Either Nucleotide-binding Fold Abolishes Drug-stimulated ATPase Activity (*) , 1995, The Journal of Biological Chemistry.
[32] M. Gottesman,et al. Altered Drug-stimulated ATPase Activity in Mutants of the Human Multidrug Resistance Protein (*) , 1996, The Journal of Biological Chemistry.
[33] P. Gros,et al. Residues in P-glycoprotein catalytic sites that react with the inhibitor 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole. , 1998, Archives of biochemistry and biophysics.
[34] S. Ambudkar,et al. Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein* , 1997, The Journal of Biological Chemistry.
[35] G. L. Kenyon,et al. Novel alkyl alkanethiolsulfonate sulfhydryl reagents. Modification of derivatives ofl-cysteine , 1982 .
[36] D. Clarke,et al. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. , 1994, Biochemistry.
[37] D. Clarke,et al. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.
[38] D. Clarke,et al. Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. , 1994, The Journal of biological chemistry.
[39] D. Clarke,et al. The Minimum Functional Unit of Human P-glycoprotein Appears to be a Monomer* , 1996, The Journal of Biological Chemistry.
[40] D. Clarke,et al. Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12* , 1997, The Journal of Biological Chemistry.
[41] D. Clarke,et al. Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities (*) , 1995, The Journal of Biological Chemistry.
[42] D. Clarke,et al. P-glycoprotein , 1995, The Journal of Biological Chemistry.
[43] D. Clarke,et al. Superfolding of the Partially Unfolded Core-glycosylated Intermediate of Human P-glycoprotein into the Mature Enzyme Is Promoted by Substrate-induced Transmembrane Domain Interactions* , 1998, The Journal of Biological Chemistry.
[44] S. Orlowski,et al. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. , 1998, The Biochemical journal.
[45] Stephan Kopp,et al. Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. , 2002, Molecular pharmacology.
[46] D. Clarke,et al. The Packing of the Transmembrane Segments of Human Multidrug Resistance P-glycoprotein Is Revealed by Disulfide Cross-linking Analysis* , 2000, The Journal of Biological Chemistry.
[47] I. Pastan,et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.
[48] D. Clarke,et al. Inhibition of Oxidative Cross-linking between Engineered Cysteine Residues at Positions 332 in Predicted Transmembrane Segments (TM) 6 and 975 in Predicted TM12 of Human P-glycoprotein by Drug Substrates* , 1996, The Journal of Biological Chemistry.
[49] Michael M. Gottesman,et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.
[50] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[51] Y. Shao,et al. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. , 1996, Biochimica et biophysica acta.
[52] D. Clarke,et al. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. , 1994, The Journal of biological chemistry.
[53] D. Clarke,et al. Determining the Dimensions of the Drug-binding Domain of Human P-glycoprotein Using Thiol Cross-linking Compounds as Molecular Rulers* , 2001, The Journal of Biological Chemistry.
[54] C. Hrycyna,et al. Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance. , 2001, Seminars in cell & developmental biology.
[55] D. Clarke,et al. Cross-linking of Human Multidrug Resistance P-glycoprotein by the Substrate, Tris-(2-maleimidoethyl)amine, Is Altered by ATP Hydrolysis , 2001, The Journal of Biological Chemistry.
[56] D. Gadsby,et al. ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. , 1997, Seminars in cancer biology.
[57] D. Clarke,et al. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. , 2000, Journal of the National Cancer Institute.